

## Supplementary Online Content

Lo AC, Liu A, Liu Q, et al. Late cardiac toxic effects associated with treatment protocols for Hodgkin lymphoma in children. *JAMA Netw Open*. 2024;7(1):e2351062.  
doi:10.1001/jamanetworkopen.2023.51062

**eTable 1.** Thirty-Year Cumulative Incidence and 95% CIs (%) of Any Cardiac Disease, Coronary Artery Disease, and Heart Failure for Average 15-Year-Old Patient With Dexrazoxane According to Cumulative Anthracycline Dose and Mean Cardiac Radiotherapy Dose

**eTable 2.** Thirty-Year Cumulative Incidence and 95% CIs (%) of Any Cardiac Disease, Coronary Artery Disease, and Heart Failure for Average 12-Year-Old Patient With Dexrazoxane According to Cumulative Anthracycline Dose and Mean Cardiac Radiotherapy Dose

**eTable 3.** Thirty-Year Cumulative Incidence and 95% CIs (%) of Any Cardiac Disease, Coronary Artery Disease, and Heart Failure for Average 18-Year-Old Patient With Dexrazoxane According to Cumulative Anthracycline Dose and Mean Cardiac Radiotherapy Dose

**eTable 4.** Thirty-Year Cumulative Incidence and 95% CIs (%) of Any Cardiac Disease, Coronary Artery Disease, and Heart Failure for Average 12-Year-Old Female With Dexrazoxane According to Cumulative Anthracycline Dose and Mean Cardiac Radiotherapy Dose

**eTable 5.** Thirty-Year Cumulative Incidence and 95% CIs (%) of Any Cardiac Disease, Coronary Artery Disease, and Heart Failure for Average 12-Year-Old-Male With Dexrazoxane According to Cumulative Anthracycline Dose and Mean Cardiac Radiotherapy Dose

**eTable 6.** Thirty-Year Cumulative Incidence and 95% CIs (%) of Any Cardiac Disease, Coronary Artery Disease and Heart Failure for Average 15-Year-Old Female With Dexrazoxane According to Cumulative Anthracycline Dose and Mean Cardiac Radiotherapy Dose

**eTable 7.** Thirty-Year Cumulative Incidence and 95% CIs (%) of Any Cardiac Disease, Coronary Artery Disease, and Heart Failure for Average 15-Year-Old Male With Dexrazoxane According to Cumulative Anthracycline Dose and Mean Cardiac Radiotherapy Dose

**eTable 8.** Thirty-Year Cumulative Incidence and 95% CIs (%) of Any Cardiac Disease, Coronary Artery Disease, and Heart Failure for Average 18-Year-Old Female With Dexrazoxane According to Cumulative Anthracycline Dose and Mean Cardiac Radiotherapy Dose

**eTable 9.** Thirty-Year Cumulative Incidence and 95% CIs (%) of Any Cardiac Disease, Coronary Artery Disease, and Heart Failure for Average 18-Year-Old Male With Dexrazoxane According to Cumulative Anthracycline Dose and Mean Cardiac Radiotherapy Dose

**eTable 10.** Thirty-Year Cumulative Incidence and 95% CIs (%) of Any Cardiac Disease, Coronary Artery Disease, and Heart Failure for Average 15-Year-Old White Female With Dexrazoxane According to Cumulative Anthracycline Dose and Mean Cardiac Radiotherapy Dose

**eTable 11.** Thirty-Year Cumulative Incidence and 95% CIs (%) of Any Cardiac Disease, Coronary Artery Disease, and Heart Failure for Average 15-Year-Old Black Female With Dexrazoxane According to Cumulative Anthracycline Dose and Mean Cardiac Radiotherapy Dose

**eTable 12.** Thirty-Year Cumulative Incidence and 95% CIs (%) of Any Cardiac Disease, Coronary Artery Disease, and Heart Failure for Average 15-Year-Old Hispanic Female With Dexrazoxane According to Cumulative Anthracycline Dose and Mean Cardiac Radiotherapy Dose

**eTable 13.** Thirty-Year Cumulative Incidence and 95% CIs (%) of Any Cardiac Disease, Coronary Artery Disease, and Heart Failure for Average 15-Year-Old White Male With Dexrazoxane According to Cumulative Anthracycline Dose and Mean Cardiac Radiotherapy Dose

**eTable 14.** Thirty-Year Cumulative Incidence and 95% CIs (%) of Any Cardiac Disease, Coronary Artery Disease, and Heart Failure for Average 15-Year-Old Black Male With Dexrazoxane According to Cumulative Anthracycline Dose and Mean Cardiac Radiotherapy Dose

**eTable 15.** Thirty-Year Cumulative Incidence and 95% CIs (%) of Any Cardiac Disease, Coronary Artery Disease, and Heart Failure for Average 15-Year-Old Hispanic Male With Dexrazoxane According to Cumulative Anthracycline Dose and Mean Cardiac Radiotherapy Dose

**eFigure 1.** Cumulative Incidence of Any Cardiac Disease Based on Mean Heart Dose for Average 15-Year-Old Patient

**eFigure 2.** Thirty-Year Cumulative Incidence of Any Cardiac Disease in the Average 12-Year-Old Female on Each Trial

This supplementary material has been provided by the authors to give readers additional information about their work.

**eTable 1.** Thirty-Year Cumulative Incidence and 95% CIs (%) of Any Cardiac Disease, Coronary Artery Disease, and Heart Failure for Average 15-Year-Old Patient With Dexrazoxane According to Cumulative Anthracycline Dose and Mean Cardiac Radiotherapy Dose

Mean cardiac RT dose, Gy	Cumulative Anthracycline Dose (mg/m <sup>2</sup> )								
	Any Cardiac Disease			Coronary Artery Disease			Heart Failure		
	200 mg/m <sup>2</sup>	250 mg/m <sup>2</sup>	300 mg/m <sup>2</sup>	200 mg/m <sup>2</sup>	250 mg/m <sup>2</sup>	300 mg/m <sup>2</sup>	200 mg/m <sup>2</sup>	250 mg/m <sup>2</sup>	300 mg/m <sup>2</sup>
0	5.4 (2.4, 10)	5.5 (2.5, 10.1)	5.7 (2.6, 10.5)	2.7 (0.6, 6.5)	2.7 (0.6, 6.5)	2.8 (0.6, 6.5)	2.2 (0.7, 4.7)	2.5 (0.7, 5.2)	2.8 (0.8, 5.8)
5	6.3 (2.8, 11.7)	6.5 (2.9, 11.9)	6.7 (3.0, 12.2)	3.2 (0.7, 7.6)	3.3 (0.7, 7.6)	3.3 (0.7, 7.6)	2.8 (0.8, 5.8)	3.1 (0.9, 6.4)	3.5 (1.1, 7.0)
10	7.4 (3.4, 10.136)	7.6 (3.5, 14.0)	7.8 (3.6, 14.3)	3.9 (0.8, 8.9)	3.9 (0.9, 9.0)	4.0 (0.9, 9.0)	3.5 (1.1, 7.2)	3.9 (1.2, 7.9)	4.4 (1.4, 8.7)
15	8.7 (4.1, 15.8)	8.9 (4.2, 16.2)	9.2 (4.2, 16.6)	4.6 (1.0, 10.8)	4.7 (1.0, 10.7)	4.7 (1.0, 10.8)	4.4 (1.4, 9.1)	4.9 (1.6, 9.8)	5.5 (1.8, 10.8)
20	10.2 (4.8, 18.6)	10.4 (4.9, 18.9)	10.8 (5.1, 19.3)	5.5 (1.2, 12.9)	5.5 (1.2, 13.0)	5.6 (1.2, 13.0)	5.6 (1.8, 11.3)	6.2 (2.1, 12.3)	6.9 (2.3, 13.4)

**eTable 2.** Thirty-Year Cumulative Incidence and 95% CIs (%) of Any Cardiac Disease, Coronary Artery Disease, and Heart Failure for Average 12-Year-Old Patient With Dexrazoxane According to Cumulative Anthracycline Dose and Mean Cardiac Radiotherapy Dose

12 year old	Cumulative Anthracycline Dose (mg/m <sup>2</sup> )								
	Any Cardiac Disease			Coronary Artery Disease			Heart Failure		
Mean cardiac RT dose, Gy	200 mg/m <sup>2</sup>	250 mg/m <sup>2</sup>	300 mg/m <sup>2</sup>	200 mg/m <sup>2</sup>	250 mg/m <sup>2</sup>	300 mg/m <sup>2</sup>	200 mg/m <sup>2</sup>	250 mg/m <sup>2</sup>	300 mg/m <sup>2</sup>
0	4.2 (1.9, 8.0)	4.3 (2.0, 8.3)	4.5 (2.0, 8.4)	2.1 (0.4, 4.9)	2.1 (0.4, 5.0)	2.1 (0.4, 5.0)	2.0 (0.6, 4.3)	2.2 (0.7, 4.7)	2.5 (0.8, 5.2)
5	5.0 (2.3, 9.2)	5.1 (2.3, 9.4)	5.3 (2.4, 9.7)	2.5 (0.5, 6.0)	2.5 (0.5, 6.0)	2.5 (0.5, 6.0)	2.5 (0.8, 5.3)	2.8 (0.9, 5.8)	3.2 (0.9, 6.4)
10	5.9 (2.7, 10.9)	6.0 (2.7, 11.1)	6.1 (2.8, 11.3)	3.0 (0.6, 7.2)	3.0 (0.6, 7.2)	3.0 (0.6, 7.2)	3.1 (1.0, 6.5)	3.5 (1.1, 7.2)	3.9 (1.2, 7.9)
15	6.9 (3.1, 12.8)	7.1 (3.2, 13.1)	7.3 (3.3, 13.4)	3.5 (0.8, 8.6)	3.6 (0.8, 8.6)	3.6 (0.8, 8.6)	3.9 (1.3, 8.1)	4.4 (1.4, 8.9)	4.9 (1.6, 9.8)
20	8.1 (3.6, 15.0)	8.3 (3.8, 15.4)	8.6 (3.9, 15.7)	4.2 (0.9, 10.3)	4.2 (0.9, 10.3)	4.3 (0.9, 10.3)	4.9 (1.7, 10.1)	5.5 (1.8, 11.0)	6.0 (2.0, 11.9)

**eTable 3.** Thirty-Year Cumulative Incidence and 95% CIs (%) of Any Cardiac Disease, Coronary Artery Disease, and Heart Failure for Average 18-Year-Old Patient With Dexrazoxane According to Cumulative Anthracycline Dose and Mean Cardiac Radiotherapy Dose

18 year old	Cumulative Anthracycline Dose (mg/m <sup>2</sup> )								
	Any Cardiac Disease			Coronary Artery Disease			Heart Failure		
Mean cardiac RT dose, Gy	200 mg/m <sup>2</sup>	250 mg/m <sup>2</sup>	300 mg/m <sup>2</sup>	200 mg/m <sup>2</sup>	250 mg/m <sup>2</sup>	300 mg/m <sup>2</sup>	200 mg/m <sup>2</sup>	250 mg/m <sup>2</sup>	300 mg/m <sup>2</sup>
0	6.9 (3.0, 12.9)	7.0 (3.1, 13.2)	7.2 (3.2, 13.4)	3.5 (0.8, 8.6)	3.6 (0.8, 8.5)	3.7 (0.8, 8.5)	2.5 (0.7, 5.5)	2.8 (0.8, 6.1)	3.1 (0.9, 6.8)
5	8.0 (3.6, 14.8)	8.2 (3.7, 15.1)	8.5 (3.7, 15.5)	4.3 (0.9, 10.0)	4.3 (1.0, 10.0)	4.4 (1.0, 10.1)	3.2 (0.9, 6.8)	3.5 (1.1, 7.4)	3.9 (1.2, 8.2)
10	9.4 (4.2, 17.1)	9.6 (4.4, 17.3)	9.9 (4.5, 17.7)	5.1 (1.1, 11.8)	5.1 (1.1, 11.9)	5.2 (1.1, 11.9)	4.0 (1.2, 8.3)	4.4 (1.4, 9.1)	4.9 (1.5, 10.1)
15	11.0 (5.1, 19.7)	11.3 (5.2, 20.1)	11.6 (5.4, 20.5)	6.1 (1.3, 14.0)	6.1 (1.3, 14.0)	6.2 (1.4, 14.0)	5.0 (1.6, 10.3)	5.5 (1.8, 11.2)	6.1 (2.0, 12.1)
20	12.9 (6.0, 23.2)	13.2 (6.2, 23.5)	13.6 (6.4, 23.8)	7.2 (1.6, 16.7)	7.2 (1.6, 16.9)	7.3 (1.6, 16.8)	6.2 (2.1, 12.6)	6.9 (2.3, 13.7)	7.6 (2.5, 15.0)

**eTable 4.** Thirty-Year Cumulative Incidence and 95% CIs (%) of Any Cardiac Disease, Coronary Artery Disease, and Heart Failure for Average 12-Year-Old Female With Dexrazoxane According to Cumulative Anthracycline Dose and Mean Cardiac Radiotherapy Dose

12 year old female	Cumulative Anthracycline Dose (mg/m <sup>2</sup> )								
	Any Cardiac Disease			Coronary Artery Disease			Heart Failure		
Mean cardiac RT dose, Gy	200 mg/m <sup>2</sup>	250 mg/m <sup>2</sup>	300 mg/m <sup>2</sup>	200 mg/m <sup>2</sup>	250 mg/m <sup>2</sup>	300 mg/m <sup>2</sup>	200 mg/m <sup>2</sup>	250 mg/m <sup>2</sup>	300 mg/m <sup>2</sup>
0	4.1 (1.8, 7.8)	4.2 (1.9, 7.9)	4.4 (1.9, 8.1)	1.5 (0.3, 3.9)	1.5 (0.3, 3.9)	1.5 (0.3, 3.9)	2.6 (0.8, 5.9)	2.9 (0.9, 6.4)	3.3 (1.0, 7.0)
5	4.9 (2.1, 9.1)	5.0 (2.2, 9.4)	5.1 (2.3, 9.5)	1.8 (0.4, 4.5)	1.8 (0.4, 4.5)	1.8 (0.4, 4.4)	3.3 (1.0, 7.1)	3.7 (1.1, 7.8)	4.2 (1.3, 8.5)
10	5.7 (2.6, 10.7)	5.8 (2.6, 11.0)	6.0 (2.7, 11.3)	2.1 (0.4, 5.4)	2.2 (0.4, 5.4)	2.2 (0.4, 5.4)	4.2 (1.3, 8.9)	4.6 (1.5, 9.6)	5.2 (1.6, 10.4)
15	6.7 (3.0, 12.5)	6.9 (3.1, 12.8)	7.1 (3.2, 13.2)	2.6 (0.5, 6.5)	2.6 (0.5, 6.6)	2.6 (0.5, 6.6)	5.3 (1.8, 11.2)	5.8 (1.9, 12.0)	6.5 (2.1, 12.9)
20	7.9 (3.5, 14.6)	8.1 (3.6, 15.0)	8.3 (3.7, 15.3)	3.1 (0.6, 7.8)	3.1 (0.6, 7.8)	3.1 (0.6, 7.9)	6.6 (2.3, 13.6)	7.3 (2.5, 14.7)	8.1 (2.7, 15.9)

**eTable 5.** Thirty-Year Cumulative Incidence and 95% Cis (%) of Any Cardiac Disease, Coronary Artery Disease, and Heart Failure for Average 12-Year-Old-Male With Dexrazoxane According to Cumulative Anthracycline Dose and Mean Cardiac Radiotherapy Dose

12 year old male	Cumulative Anthracycline Dose (mg/m <sup>2</sup> )								
	Any Cardiac Disease			Coronary Artery Disease			Heart Failure		
Mean cardiac RT dose, Gy	200 mg/m <sup>2</sup>	250 mg/m <sup>2</sup>	300 mg/m <sup>2</sup>	200 mg/m <sup>2</sup>	250 mg/m <sup>2</sup>	300 mg/m <sup>2</sup>	200 mg/m <sup>2</sup>	250 mg/m <sup>2</sup>	300 mg/m <sup>2</sup>
0	4.3 (2.0, 8.2)	4.4 (2.0, 8.5)	4.6 (2.1, 8.7)	2.6 (0.5, 6.3)	2.6 (0.5, 6.3)	2.7 (0.5, 6.4)	1.3 (0.4, 3.0)	1.4 (0.4, 3.3)	1.6 (0.5, 3.6)
5	5.1 (2.3, 9.6)	5.2 (2.4, 9.8)	5.4 (2.4, 10.0)	3.1 (0.7, 7.4)	3.2 (0.7, 7.3)	3.2 (0.7, 7.4)	1.6 (0.5, 3.7)	1.8 (0.6, 4.1)	2.0 (0.6, 4.4)
10	6.0 (2.7, 11.3)	6.1 (2.8, 11.6)	6.3 (2.9, 11.8)	3.7 (0.8, 9.0)	3.8 (0.8, 9.0)	3.8 (0.8, 9.0)	2.1 (0.7, 4.6)	2.3 (0.7, 5.0)	2.6 (0.8, 5.5)
15	7.0 (3.2, 13.2)	7.2 (3.2, 13.4)	7.4 (3.4, 13.7)	4.4 (0.9, 10.7)	4.4 (1.0, 10.6)	4.5 (1.0, 10.7)	2.6 (0.9, 5.8)	2.9 (0.9, 6.3)	3.2 (1.1, 6.8)
20	8.2 (3.7, 15.5)	8.5 (3.9, 15.6)	8.7 (4.0, 16.0)	5.3 (1.1, 12.7)	5.3 (1.1, 12.8)	5.4 (1.1, 12.8)	3.2 (1.1, 7.3)	3.6 (1.2, 7.9)	4.0 (1.3, 8.5)

**eTable 6.** Thirty-Year Cumulative Incidence and 95% CIs (%) of Any Cardiac Disease, Coronary Artery Disease and Heart Failure for Average 15-Year-Old Female With Dexrazoxane According to Cumulative Anthracycline Dose and Mean Cardiac Radiotherapy Dose

15 year old females	Cumulative Anthracycline Dose (mg/m <sup>2</sup> )								
	Any Cardiac Disease			Coronary Artery Disease			Heart Failure		
Mean cardiac RT dose, Gy	200 mg/m <sup>2</sup>	250 mg/m <sup>2</sup>	300 mg/m <sup>2</sup>	200 mg/m <sup>2</sup>	250 mg/m <sup>2</sup>	300 mg/m <sup>2</sup>	200 mg/m <sup>2</sup>	250 mg/m <sup>2</sup>	300 mg/m <sup>2</sup>
0	5.3 (2.3, 9.8)	5.4 (2.4, 9.9)	5.6 (2.4, 10.2)	2.0 (0.4, 4.9)	2.0 (0.4, 4.8)	2.0 (0.4, 4.9)	3.0 (0.9, 6.4)	3.3 (1.0, 7.0)	3.7 (1.1, 7.8)
5	6.2 (2.8, 11.5)	6.4 (2.9, 11.8)	6.5 (2.9, 12.0)	2.4 (0.5, 5.8)	2.4 (0.5, 5.8)	2.4 (0.5, 5.8)	3.7 (1.1, 7.8)	4.1 (1.3, 8.7)	4.6 (1.4, 9.5)
10	7.3 (3.3, 13.3)	7.5 (3.4, 13.6)	7.7 (3.5, 14.0)	2.9 (0.6, 6.9)	2.9 (0.6, 6.9)	2.9 (0.6, 7.0)	4.7 (1.5, 9.8)	5.2 (1.6, 10.6)	5.8 (1.8, 11.6)
15	8.4 (3.9, 15.6)	8.7 (4.0, 15.9)	8.9 (4.1, 16.3)	3.4 (0.7, 8.3)	3.5 (0.7, 8.3)	3.5 (0.7, 8.4)	5.9 (1.9, 12.1)	6.5 (2.1, 13.1)	7.2 (2.3, 14.3)
20	10.0 (4.5, 18.2)	10.2 (4.7, 18.6)	10.4 (4.8, 19.1)	4.1 (0.8, 10.0)	4.1 (0.8, 10.1)	4.2 (0.8, 10.1)	7.4 (2.5, 15.0)	8.1 (2.8, 16.2)	9.0 (3.1, 17.6)



**eTable 7.** Thirty-Year Cumulative Incidence and 95% CIs (%) of Any Cardiac Disease, Coronary Artery Disease, and Heart Failure for Average 15-Year-Old Male With Dexrazoxane According to Cumulative Anthracycline Dose and Mean Cardiac Radiotherapy Dose

15 year old male	Cumulative Anthracycline Dose (mg/m <sup>2</sup> )								
	Any Cardiac Disease			Coronary Artery Disease			Heart Failure		
	Mean cardiac RT dose, Gy	200 mg/m <sup>2</sup>	250 mg/m <sup>2</sup>	300 mg/m <sup>2</sup>	200 mg/m <sup>2</sup>	250 mg/m <sup>2</sup>	300 mg/m <sup>2</sup>	200 mg/m <sup>2</sup>	250 mg/m <sup>2</sup>
0	5.5 (2.5, 10.3)	5.6 (2.6, 10.5)	5.8 (2.7, 10.7)	3.4 (0.7, 8.2)	3.5 (0.7, 8.1)	3.5 (0.8, 8.2)	1.4 (0.4, 3.5)	1.6 (0.5, 3.8)	1.8 (0.5, 4.2)
5	6.5 (3.0, 12.0)	6.6 (3.1, 12.2)	6.8 (3.2, 12.6)	4.1 (0.9, 9.6)	4.2 (0.9, 9.6)	4.2 (0.9, 9.6)	1.8 (0.6, 4.2)	2.0 (0.6, 4.5)	2.3 (0.7, 5.0)
10	7.5 (3.5, 14.0)	7.8 (3.6, 14.2)	8.0 (3.7, 14.6)	4.9 (1.0, 11.3)	5.0 (1.0, 11.2)	5.0 (1.1, 11.4)	2.3 (0.7, 5.3)	2.6 (0.8, 5.7)	2.9 (0.9, 6.2)
15	8.9 (4.1, 16.3)	9.1 (4.3, 16.7)	9.4 (4.3, 17.0)	5.9 (1.2, 13.3)	5.9 (1.3, 13.2)	5.9 (1.3, 13.5)	2.9 (0.9, 6.5)	3.2 (1.0, 7.1)	3.6 (1.2, 7.8)
20	10.4 (4.8, 18.9)	10.7 (4.9, 19.3)	11.0 (5.1, 19.7)	6.9 (1.5, 15.9)	6.9 (1.5, 16.0)	7.0 (1.5, 16.1)	3.6 (1.2, 8.1)	4.1 (1.3, 8.8)	4.6 (1.5, 9.6)

**eTable 8.** Thirty-Year Cumulative Incidence and 95% CIs (%) of Any Cardiac Disease, Coronary Artery Disease, and Heart Failure for Average 18-Year-Old Female With Dexrazoxane According to Cumulative Anthracycline Dose and Mean Cardiac Radiotherapy Dose

18 year old female	Cumulative Anthracycline Dose (mg/m <sup>2</sup> )								
	Any Cardiac Disease			Coronary Artery Disease			Heart Failure		
Mean cardiac RT dose, Gy	200 mg/m <sup>2</sup>	250 mg/m <sup>2</sup>	300 mg/m <sup>2</sup>	200 mg/m <sup>2</sup>	250 mg/m <sup>2</sup>	300 mg/m <sup>2</sup>	200 mg/m <sup>2</sup>	250 mg/m <sup>2</sup>	300 mg/m <sup>2</sup>
0	6.7 (2.8, 12.5)	6.9 (2.9, 12.7)	7.1 (3.0, 13.0)	2.6 (0.6, 6.4)	2.6 (0.6, 6.4)	2.7 (0.6, 6.5)	3.4 (0.9, 7.3)	3.7 (1.1, 8.1)	4.1 (1.2, 8.9)
5	7.9 (3.4, 14.4)	8.1 (3.5, 14.8)	8.3 (3.6, 15.1)	3.1 (0.7, 7.5)	3.2 (0.7, 7.6)	3.2 (0.7, 7.6)	4.2 (1.2, 8.9)	4.6 (1.4, 9.7)	5.2 (1.6, 10.7)
10	9.2 (4.1, 16.7)	9.4 (4.2, 17.0)	9.7 (4.4, 17.7)	3.8 (0.8, 9.1)	3.8 (0.8, 9.1)	3.8 (0.8, 9.1)	5.3 (1.6, 11.0)	5.8 (1.8, 11.9)	6.5 (2.0, 13.2)
15	10.7 (4.9, 19.4)	11.0 (5.0, 20.0)	11.3 (5.2, 20.4)	4.5 (0.9, 10.9)	4.5 (0.9, 10.8)	4.6 (1.0, 10.9)	6.6 (2.1, 13.5)	7.3 (2.3, 14.7)	8.1 (2.5, 16.2)
20	12.6 (5.7, 22.6)	12.9 (5.9, 23.1)	13.2 (6.1, 23.6)	5.4 (1.1, 12.8)	5.4 (1.1, 12.9)	5.5 (1.1, 13.1)	8.3 (2.7, 16.8)	9.1 (3.0, 18.0)	10.1 (3.3, 19.8)

**eTable 9.** Thirty-Year Cumulative Incidence and 95% CIs (%) of Any Cardiac Disease, Coronary Artery Disease, and Heart Failure for Average 18-Year-Old Male With Dexrazoxane According to Cumulative Anthracycline Dose and Mean Cardiac Radiotherapy Dose

18 year old male	Cumulative Anthracycline Dose (mg/m <sup>2</sup> )								
	Any Cardiac Disease			Coronary Artery Disease			Heart Failure		
Mean cardiac RT dose, Gy	200 mg/m <sup>2</sup>	250 mg/m <sup>2</sup>	300 mg/m <sup>2</sup>	200 mg/m <sup>2</sup>	250 mg/m <sup>2</sup>	300 mg/m <sup>2</sup>	200 mg/m <sup>2</sup>	250 mg/m <sup>2</sup>	300 mg/m <sup>2</sup>
0	7.0 (3.1, 13.0)	7.2 (3.2, 13.1)	7.4 (3.3, 13.5)	4.5 (1.0, 10.8)	4.6 (1.0, 10.9)	4.6 (1.0, 10.9)	1.6 (0.5, 3.9)	1.8 (0.5, 4.3)	2.0 (0.6, 4.9)
5	8.2 (3.7, 15.0)	8.4 (3.9, 15.3)	8.7 (4.1, 15.6)	5.4 (1.1, 12.7)	5.5 (1.2, 12.7)	5.5 (1.2, 12.8)	2.1 (0.6, 4.8)	2.3 (0.7, 5.3)	2.6 (0.8, 5.9)
10	9.6 (4.4, 17.5)	9.9 (4.6, 17.8)	10.2 (4.7, 18.1)	6.5 (1.4, 15.1)	6.5 (1.4, 15.2)	6.6 (1.4, 15.1)	2.6 (0.8, 6.0)	2.9 (0.9, 6.6)	3.2 (1.0, 7.2)
15	11.3 (5.2, 20.2)	11.6 (5.3, 20.6)	11.9 (5.5, 21.1)	7.7 (1.7, 17.6)	7.8 (1.7, 17.7)	7.8 (1.7, 17.8)	3.3 (1.0, 7.4)	3.6 (1.1, 8.1)	4.1 (1.2, 8.9)
20	13.1 (6.3, 23.5)	13.5 (6.4, 23.9)	13.9 (6.6, 24.1)	9.1 (2.0, 20.8)	9.2 (2.0, 21.0)	9.3 (2.0, 21.0)	4.1 (1.3, 9.2)	4.6 (1.5, 10.0)	5.1 (1.6, 10.9)

**eTable 10.** Thirty-Year Cumulative Incidence and 95% CIs (%) of Any Cardiac Disease, Coronary Artery Disease, and Heart Failure for Average 15-Year-Old White Female With Dexrazoxane According to Cumulative Anthracycline Dose and Mean Cardiac Radiotherapy Dose

15 year old white female	Cumulative Anthracycline Dose (mg/m <sup>2</sup> )								
	Any Cardiac Disease			Coronary Artery Disease			Heart Failure		
	Mean cardiac RT dose, Gy	200 mg/m <sup>2</sup>	250 mg/m <sup>2</sup>	300 mg/m <sup>2</sup>	200 mg/m <sup>2</sup>	250 mg/m <sup>2</sup>	300 mg/m <sup>2</sup>	200 mg/m <sup>2</sup>	250 mg/m <sup>2</sup>
0	5.1 (2.2, 9.5)	5.3 (2.2, 9.6)	5.4 (2.3, 9.9)	1.9 (0.4, 4.9)	1.9 (0.4, 4.9)	2.0 (0.4, 5.0)	2.8 (0.8, 6.0)	3.1 (0.9, 6.6)	3.5 (1.0, 7.3)
5	6.0 (2.5, 11.0)	6.2 (2.6, 11.3)	6.3 (2.7, 11.6)	2.3 (0.5, 5.8)	2.3 (0.5, 5.8)	2.4 (0.5, 5.9)	3.5 (1.1, 7.3)	3.9 (1.2, 8.1)	4.4 (1.4, 8.9)
10	7.0 (3.1, 12.9)	7.2 (3.1, 13.4)	7.4 (3.2, 13.6)	2.8 (0.5, 6.9)	2.8 (0.5, 6.9)	2.8 (0.6, 6.9)	4.4 (1.4, 9.1)	4.9 (1.6, 9.9)	5.5 (1.8, 10.9)
15	8.2 (3.7, 15.1)	8.4 (3.7, 15.6)	8.7 (3.9, 16.0)	3.3 (0.7, 8.2)	3.3 (0.7, 8.2)	3.4 (0.7, 8.2)	5.6 (1.8, 11.3)	6.1 (2.1, 12.2)	6.9 (2.3, 13.4)
20	9.6 (4.2, 17.6)	9.8 (4.4, 18.1)	10.1 (4.6, 18.7)	4.0 (0.8, 9.8)	4.0 (0.8, 9.8)	4.0 (0.8, 9.9)	6.9 (2.4, 13.9)	7.6 (2.7, 15.1)	8.5 (3.0, 16.5)

**eTable 11.** Thirty-Year Cumulative Incidence and 95% CIs (%) of Any Cardiac Disease, Coronary Artery Disease, and Heart Failure for Average 15-Year-Old Black Female With Dexrazoxane According to Cumulative Anthracycline Dose and Mean Cardiac Radiotherapy Dose

15 year old black female	Cumulative Anthracycline Dose (mg/m <sup>2</sup> )								
	Any Cardiac Disease			Coronary Artery Disease			Heart Failure		
	Mean cardiac RT dose, Gy	200 mg/m <sup>2</sup>	250 mg/m <sup>2</sup>	300 mg/m <sup>2</sup>	200 mg/m <sup>2</sup>	250 mg/m <sup>2</sup>	300 mg/m <sup>2</sup>	200 mg/m <sup>2</sup>	250 mg/m <sup>2</sup>
0	6.2 (2.5, 12.1)	6.4 (2.5, 12.3)	6.6 (2.6, 12.5)	2.2 (0.4, 6.0)	2.2 (0.4, 6.0)	2.2 (0.4, 6.0)	3.8 (1.1, 8.7)	4.3 (1.2, 9.6)	4.8 (1.4, 10.7)
5	7.3 (3.0, 13.9)	7.4 (3.0, 14.2)	7.7 (3.1, 14.4)	2.6 (0.5, 7.1)	2.6 (0.5, 7.1)	2.7 (0.5, 7.1)	4.8 (1.4, 10.6)	5.3 (1.6, 11.5)	5.9 (1.8, 12.8)
10	8.5 (3.6, 16.0)	8.7 (3.7, 16.3)	9.0 (3.8, 16.7)	3.1 (0.6, 8.3)	3.2 (0.6, 8.4)	3.2 (0.6, 8.3)	6.0 (1.8, 13.1)	6.6 (2.0, 14.3)	7.4 (2.2, 15.6)
15	9.9 (4.3, 18.6)	10.1 (4.4, 18.8)	10.4 (4.5, 19.3)	3.7 (0.7, 9.9)	3.8 (0.7, 9.8)	3.8 (0.7, 10.1)	7.4 (2.3, 15.9)	8.3 (2.5, 17.0)	9.3 (2.8, 18.6)
20	11.5 (5.0, 21.4)	11.8 (5.2, 21.8)	12.1 (5.3, 22.3)	4.4 (0.8, 11.8)	4.5 (0.8, 11.8)	4.5 (0.8, 11.8)	9.2 (2.9, 19.5)	10.2 (3.2, 20.8)	11.3 (3.6, 22.5)

**eTable 12.** Thirty-Year Cumulative Incidence and 95% CIs (%) of Any Cardiac Disease, Coronary Artery Disease, and Heart Failure for Average 15-Year-Old Hispanic Female With Dexrazoxane According to Cumulative Anthracycline Dose and Mean Cardiac Radiotherapy Dose

15 year old Hispanic female	Cumulative Anthracycline Dose (mg/m <sup>2</sup> )								
	Any Cardiac Disease			Coronary Artery Disease			Heart Failure		
	Mean cardiac RT dose, Gy	200 mg/m <sup>2</sup>	250 mg/m <sup>2</sup>	300 mg/m <sup>2</sup>	200 mg/m <sup>2</sup>	250 mg/m <sup>2</sup>	300 mg/m <sup>2</sup>	200 mg/m <sup>2</sup>	250 mg/m <sup>2</sup>
0	4.9 (2.2, 9.3)	5.0 (2.2, 9.5)	5.2 (2.3, 9.8)	1.8 (0.4, 4.6)	1.9 (0.4, 4.6)	1.9 (0.4, 4.6)	2.8 (0.8, 6.1)	3.1 (0.9, 6.7)	3.5 (1.0, 7.4)
5	5.7 (2.5, 10.8)	5.9 (2.6, 11.1)	6.1 (2.7, 11.2)	2.2 (0.4, 5.4)	2.3 (0.5, 5.4)	2.3 (0.5, 5.4)	3.5 (1.0, 7.6)	3.9 (1.2, 8.3)	4.3 (1.3, 9.1)
10	6.7 (3.0, 12.5)	6.9 (3.1, 12.8)	7.1 (3.2, 13.1)	2.7 (0.5, 6.4)	2.7 (0.5, 6.4)	2.7 (0.5, 6.4)	4.4 (1.4, 9.6)	4.8 (1.5, 10.4)	5.4 (1.7, 11.1)
15	7.8 (3.6, 14.6)	8.1 (3.7, 15.0)	8.3 (3.8, 15.3)	3.2 (0.6, 7.6)	3.2 (0.7, 7.6)	3.2 (0.7, 7.6)	5.5 (1.8, 11.7)	6.0 (2.1, 12.5)	6.7 (2.3, 13.6)
20	9.2 (4.2, 17.1)	9.5 (4.4, 17.4)	9.8 (4.5, 17.7)	3.8 (0.8, 9.2)	3.8 (0.8, 9.3)	3.9 (0.8, 9.3)	6.8 (2.3, 14.3)	7.5 (2.6, 15.4)	8.3 (2.9, 16.6)

**eTable 13.** Thirty-Year Cumulative Incidence and 95% CIs (%) of Any Cardiac Disease, Coronary Artery Disease, and Heart Failure for Average 15-Year-Old White Male With Dexrazoxane According to Cumulative Anthracycline Dose and Mean Cardiac Radiotherapy Dose

15 year old white male	Cumulative Anthracycline Dose (mg/m <sup>2</sup> )								
	Any Cardiac Disease			Coronary Artery Disease			Heart Failure		
	Mean cardiac RT dose, Gy	200 mg/m <sup>2</sup>	250 mg/m <sup>2</sup>	300 mg/m <sup>2</sup>	200 mg/m <sup>2</sup>	250 mg/m <sup>2</sup>	300 mg/m <sup>2</sup>	200 mg/m <sup>2</sup>	250 mg/m <sup>2</sup>
0	5.4 (2.4, 9.9)	5.5 (2.5, 10.0)	5.7 (2.6, 10.1)	3.3 (0.7, 8.0)	3.4 (0.7, 8.1)	3.4 (0.7, 8.1)	1.4 (0.4, 3.3)	1.5 (0.5, 3.5)	1.7 (0.5, 3.9)
5	6.3 (2.9, 11.5)	6.5 (3.0, 11.6)	6.7 (3.0, 11.9)	4.0 (0.8, 9.4)	4.0 (0.8, 9.5)	4.1 (0.9, 9.4)	1.7 (0.5, 4.0)	1.9 (0.6, 4.4)	2.2 (0.7, 4.9)
10	7.4 (3.4, 13.3)	7.6 (3.4, 13.6)	7.8 (3.5, 13.9)	4.8 (1.0, 11.1)	4.8 (1.0, 11.0)	4.8 (1.0, 11.1)	2.2 (0.7, 4.9)	2.4 (0.8, 5.3)	2.7 (0.8, 5.8)
15	8.7 (3.9, 15.4)	8.9 (4.0, 15.8)	9.2 (4.1, 16.1)	5.7 (1.2, 13.2)	5.7 (1.2, 13.1)	5.8 (1.3, 13.2)	2.7 (0.9, 5.9)	3.1 (1.0, 6.4)	3.4 (1.1, 7.1)
20	10.2 (4.7, 18.2)	10.4 (4.8, 18.4)	10.7 (4.9, 18.7)	6.8 (1.4, 15.6)	6.8 (1.4, 15.8)	6.8 (1.4, 16.0)	3.4 (1.1, 7.3)	3.8 (1.2, 8.0)	4.3 (1.4, 8.9)

**eTable 14.** Thirty-Year Cumulative Incidence and 95% CIs (%) of Any Cardiac Disease, Coronary Artery Disease, and Heart Failure for Average 15-Year-Old Black Male With Dexrazoxane According to Cumulative Anthracycline Dose and Mean Cardiac Radiotherapy Dose


15 year old black male	Cumulative Anthracycline Dose (mg/m <sup>2</sup> )								
	Any Cardiac Disease			Coronary Artery Disease			Heart Failure		
	Mean cardiac RT dose, Gy	200 mg/m <sup>2</sup>	250 mg/m <sup>2</sup>	300 mg/m <sup>2</sup>	200 mg/m <sup>2</sup>	250 mg/m <sup>2</sup>	300 mg/m <sup>2</sup>	200 mg/m <sup>2</sup>	250 mg/m <sup>2</sup>
0	6.4 (2.7, 12.4)	6.6 (2.8, 12.7)	6.8 (2.9, 12.9)	3.7 (0.7, 9.5)	3.7 (0.7, 9.7)	3.8 (0.7, 9.7)	1.9 (0.5, 4.8)	2.1 (0.6, 5.3)	2.4 (0.6, 5.9)
5	7.5 (3.3, 14.5)	7.7 (3.4, 14.7)	7.9 (3.4, 15.1)	4.4 (0.8, 11.4)	4.4 (0.8, 11.6)	4.5 (0.9, 11.6)	2.4 (0.7, 5.9)	2.6 (0.7, 6.4)	3.0 (0.8, 7.1)
10	8.7 (3.8, 16.8)	9.0 (3.9, 17.2)	9.2 (4.0, 17.4)	5.3 (0.9, 13.5)	5.3 (1.0, 13.5)	5.4 (1.0, 13.7)	3.0 (0.9, 7.2)	3.3 (1.0, 7.8)	3.7 (1.1, 8.7)
15	10.2 (4.4, 19.3)	10.5 (4.6, 19.5)	10.8 (4.8, 20.0)	6.3 (1.1, 16.0)	6.4 (1.2, 16.1)	6.4 (1.2, 16.0)	3.7 (1.1, 8.8)	4.1 (1.2, 9.5)	4.6 (1.4, 10.4)
20	12.0 (5.2, 22.1)	12.2 (5.4, 22.4)	12.6 (5.5, 22.9)	7.5 (1.3, 18.8)	7.5 (1.3, 18.9)	7.6 (1.3, 18.8)	4.7 (1.5, 11.0)	5.2 (1.7, 11.7)	5.8 (1.9, 13.0)



**eTable 15.** Thirty-Year Cumulative Incidence and 95% CIs (%) of Any Cardiac Disease, Coronary Artery Disease, and Heart Failure for Average 15-Year-Old Hispanic Male With Dexrazoxane According to Cumulative Anthracycline Dose and Mean Cardiac Radiotherapy Dose

15 year old Hispanic male	Cumulative Anthracycline Dose (mg/m <sup>2</sup> )								
	Any Cardiac Disease			Coronary Artery Disease			Heart Failure		
	Mean cardiac RT dose, Gy	200 mg/m <sup>2</sup>	250 mg/m <sup>2</sup>	300 mg/m <sup>2</sup>	200 mg/m <sup>2</sup>	250 mg/m <sup>2</sup>	300 mg/m <sup>2</sup>	200 mg/m <sup>2</sup>	250 mg/m <sup>2</sup>
0	5.0 (2.3, 9.7)	5.2 (2.4, 9.9)	5.4 (2.5, 10.1)	3.2 (0.7, 7.7)	3.3 (0.7, 7.7)	3.3 (0.7, 7.9)	1.4 (0.4, 3.3)	1.5 (0.4, 3.6)	1.7 (0.5, 4.0)
5	5.9 (2.8, 11.2)	6.1 (2.9, 11.3)	6.3 (3.0, 11.7)	3.9 (0.8, 9.2)	3.9 (0.9, 9.2)	4.0 (0.9, 9.2)	1.7 (0.5, 4.1)	1.9 (0.6, 4.4)	2.2 (0.6, 4.9)
10	7.0 (3.3, 13.0)	7.2 (3.4, 13.3)	7.5 (3.5, 13.6)	4.6 (1.0, 10.9)	4.7 (1.0, 10.9)	4.7 (1.0, 11.0)	2.2 (0.7, 4.9)	2.4 (0.7, 5.4)	2.7 (0.8, 6.0)
15	8.2 (3.9, 15.1)	8.5 (4.0, 15.5)	8.7 (4.1, 15.9)	5.6 (1.2, 13.2)	5.6 (1.2, 13.1)	5.6 (1.2, 13.0)	2.7 (0.8, 6.1)	3.0 (0.9, 6.7)	3.4 (1.0, 7.4)
20	9.7 (4.5, 17.8)	9.9 (4.7, 18.3)	10.2 (4.9, 18.7)	6.5 (1.4, 15.3)	6.6 (1.4, 15.4)	6.7 (1.5, 15.7)	3.4 (1.1, 7.7)	3.8 (1.2, 8.4)	4.2 (1.3, 9.2)

**eFigure 1.** Cumulative Incidence of Any Cardiac Disease Based on Mean Heart Dose for Average 15-Year-Old Patient. A: Doxorubicin=200mg/m<sup>2</sup> with dexrazoxane; B: Doxorubicin=250mg/m<sup>2</sup> with dexrazoxane; C: Doxorubicin=300mg/m<sup>2</sup> with dexrazoxane.



**eFigure 2.** Thirty-Year Cumulative Incidence of Any Cardiac Disease in the Average 12-Year-Old Female on Each Trial. S2-A: AHOD0031 standard arm (85% mediastinal RT); S2-B: AHOD0031 experimental arm (40% mediastinal RT); S2-C: AHOD0831; S2-D: AHOD1331; S2-E: S1826.

